Oculis îl numește pe domnul Webb Ding în funcția de Global Chief Operating Officer și Director General (China)

LAUSANNE, Switzerland, Jan 5, 2022 – (ACN Newswire) – Oculis S.A. ("Oculis"), a late-stage biopharmaceutical company focused on developing transformative ophthalmic treatments to improve the sight and lives of patients, announces the appointment of Mr. Webb Ding as global Chief Operating Officer and General Manager, China, with effect from February 1, 2022. Mr. Ding brings vast healthcare leadership experience, with a specific focus on China market.

Mr. Ding will join the Oculis Executive Leadership Team, where his decades of experience in multinational pharmaceutical company operations will help drive the company forward as it continues to develop its product pipeline and scale globally. The appointment of Mr. Ding also further strengthens Oculis' development efforts in the Greater China region, following the establishment of a Hong Kong presence earlier in the year.

Riad Sherif, M.D., CEO of Oculis, said: "We are delighted to have Webb join Oculis as our global Chief Operating Officer and General Manager, China. He brings decades of experience in healthcare across multiple segments, including unique experiences in successful brand launches and portfolio build up in the Greater China market. His in-depth knowledge of business development and licensing will be an invaluable asset to our global executive leadership team as we continue to develop a portfolio of transformative ophthalmology treatments to improve the sight and lives of patients."

Webb Ding added: "I am excited to be joining Oculis, a company dedicated to transforming the lives of patients impacted by eye diseases. There are many patients around the world in need of effective, safe and easy-to-administer topical eye medicines such as those currently being developed by Oculis. I look forward to helping to bring these much-needed treatments to patients as soon as possible."

Mr. Ding has more than 25 years of experience in general management, successful go-to-market strategies, business development and licensing, and operational excellence across multiple healthcare segments. He joins Oculis from Fresenius-Kabi, one of the top 10 multinational pharmaceutical companies in China, where he served as Country President for China, building market leadership and a strong competitive portfolio. Prior to Fresenius-Kabi, Mr. Ding spent more than 10 years with Novartis in China in leadership roles of increasing responsibility, culminating in his appointment as General Manager of Novartis Vaccines Greater China and Tianyuan Bio-Pharma. Mr. Ding was also a member of the Global Executive Committee of Novartis Vaccines.

Prior to Novartis, Mr. Ding held various senior roles in sales, marketing and distribution at major pharmaceutical companies in China including Bristol Myers Squibb and Xi'an Janssen (a Johnson & Johnson company).

Mr. Ding gained his Bachelor of Science in biochemistry from Wuhan University and completed an EMBA at the China Europe International Business School.

Despre Oculis
Cu sediul central în Lausanne, Elveția, cu operațiuni globale în Europa, SUA și China, Oculis este o companie biofarmaceutică axată pe dezvoltarea de tratamente oftalmice inovatoare transformatoare pentru a îmbunătăți vederea și viața pacienților. Oculis are un portofoliu de dezvoltare robust și extins, care include tratamente topice noi (picături pentru ochi) în stadiu avansat, care sunt non-invazive și reprezintă un progres tehnic fără precedent pentru pacienții cu edem retinian și boli din fața ochiului. În plus, capacitățile de descoperire și inovare a formulării Oculis permit dezvoltarea unei game de medicamente topice care vizează bolile oculare care amenință vederea și care afectează atât segmentele anterioare, cât și cele posterioare ale ochiului.
Pentru a afla mai multe, vă rugăm să vizitați www.oculis.com



Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comOculis S.A. ("Oculis"), a late-stage biopharmaceutical company focused on developing transformative ophthalmic treatments to improve the sight and lives of patients, announces the appointment of Mr. Webb Ding as global Chief Operating Officer and General Manager, China, with effect from February 1, 2022. Sursă: https://www.acnnewswire.com/press-release/english/72225/